Stockscreener 앱 받기
1.54
5.52%
-0.09
전일 마감가:
$1.63
열려 있는:
$1.59
하루 거래량:
930.77K
Relative Volume:
0.81
시가총액:
$237.54M
수익:
$42.17M
순이익/손실:
$-183.12M
주가수익비율:
-1.0575
EPS:
-1.4562
순현금흐름:
$-138.51M
1주 성능:
+6.21%
1개월 성능:
+13.24%
6개월 성능:
-8.88%
1년 성능:
+77.58%
1일 변동 폭
$1.525
$1.64
1주일 범위
$1.425
$1.71
52주 변동 폭
$0.81
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
명칭
Coherus Oncology Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.54 | 237.54M | 42.17M | -183.12M | -138.51M | -1.4562 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Oppenheimer | Outperform |
| 2025-09-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus BioSciences stock stays supported by oncology focus - ad-hoc-news.de
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing - ad-hoc-news.de
CHRS Stock Price, Quote & Chart - ChartMill
CHRSCoherus Oncology Inc Options - Finviz
Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView
Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView
CHRS Q1 2026 Earnings: Strong EPS Beat Highlights Operational ProgressEarnings Quality Analysis - dars.gov.et
CHRS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainOperating Income Trends - dars.gov.et
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView
CHRS Should I Buy - Intellectia AI
Coherus Oncology, Inc. Actuals & Estimates (NASDAQ:CHRS) - TradingView
8C5 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Price to sales forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Coherus Oncology (CHRS) Proxy filing Summary - Quartr
Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics - marketscreener.com
Coherus and Zumutor announce phase 1 cancer trial collaboration - Investing.com
Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com - Investing.com India
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Oncology and Zumutor Biologics Announce Phase 1 Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI - Quiver Quantitative
Coherus and Zumutor Biologics Announce Clinical - GlobeNewswire
Coherus doses first patient in cancer combo trial with Zumutor - Stock Titan
Coherus Oncology (CHRS) Slides Amid Sector Weakness, Testing Key Support LevelsBox Spread - dars.gov.et
COHERUS ONCOLOGY INC (CHRS) Stock Chart - ChartMill
Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com Australia
[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan
Coherus Oncology (CHRS) Slides 1.41% as Stock Tests Key Support at $1.33Momentum Stock Picks - dars.gov.et
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan
[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan
CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan
Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart
Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa
Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing - Stock Titan
Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN
TD Cowen Maintains Coherus Oncology(CHRS.US) With Buy Rating - Moomoo
Coherus Oncology (CHRS) AGM 2026 Summary - Quartr
CHRS: All proposals passed except the stock option price reduction, which was adjourned - TradingView
CHRS: Directors and key proposals were approved; stock option vote adjourned to May 29, 2026 - TradingView
Coherus Oncology Inc. (CHRS) Rises 2.55%: Key Levels to Watch After Support HoldLast Point Resistance - dars.gov.et
Coherus Oncology (CHRS) Holds Above Support After Modest GainNAAIM Exposure - newsline.com
Coherus Oncology Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):